Works matching AU Saydam, G.


Results: 9
    1

    Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

    Published in:
    Hematological Oncology, 2023, v. 41, p. 575, doi. 10.1002/hon.3164_431
    By:
    • McDonald, A.;
    • Verburgh, E.;
    • Gotti, M.;
    • Pinto, A.;
    • Zaucha, J.;
    • Ivanov, V.;
    • Melnichenko, V.;
    • Mocikova, H.;
    • Ozcan, M.;
    • Patti, C.;
    • Farias, J.;
    • Goncalves, I.;
    • Kuchkova, O.;
    • Mayer, J.;
    • Saydam, G.;
    • Tomassetti, S.;
    • Pathiraja, K.;
    • Ryland, K.;
    • Chakraborty, S.;
    • Jurczak, W.
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9